Market forces driving growth of the exosome have been expanding over the past two years, with increasing investment flowing into the space, merger and acquisition (M&A) activity accelerating, and new therapeutics entering various stages of development. Exosomes are defined as small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells. They are made in some form by all species, including bacteria that produce analogous outer membrane vesicles (OMC). [Read more…]
NeurExo Sciences to Host Teach-in Featuring Michael Chopp, PhD and Pioneering Exosome Technology
— Research indicates exosomes have therapeutic potential for improving recovery after stroke, traumatic brain injury —
ATLANTA and DETROIT, January 23, 2019 – NeurExo Sciences, LLC (NXS), a biopharmaceutical company and subsidiary of NeuroTrauma Sciences, LLC, will be hosting a teach-in event featuring leading exosome researcher, Michael Chopp, Ph.D., Vice Chairman, Department of Neurology and Scientific Director, Neurosciences Institute, Zoltan J. Kovacs Chair of Neuroscience Research at Henry Ford Health System (HFHS), Detroit, and Distinguished Professor of Physics, Oakland University (MI). Dr. Chopp’s presentation will provide a primer and overview of exosomes, small extracellular vesicles that provide a means of mediating intercellular communication. He also will focus on his team’s pioneering technology employing exosomes engineered with enriched microRNA for the purpose of treating neurological disease and injury, including stroke and traumatic brain injury (TBI). [Read more…]
Stem Cell Medicine Licenses Exosome Technology for Treating Autism From Ramot at Tel Aviv University
MSC-exo Technology Has Potential to Treat Autism Using Novel Intranasal Administration
Preclinical Studies Have Demonstrated a Benefit on Core Autism Symptoms
Jerusalem, Israel – Stem Cell Medicine Ltd. (SCM), a biotechnology company developing new therapies for neurological indications, including mesenchymal stem cells and anti-BMP molecules for the treatment of Multiple Sclerosis, and gene therapy for the treatment of neuropathic pain, has licensed an innovative exosomes based technology for the treatment of neurodegenerative and neuropsychiatric indications, specifically, autism spectrum disorder (ASD). The treatment is based on vesicles, exosomes, derived from adult stem cells (MSC-exo) that are administered intranasally. The technology was developed by Professor Dani Offen, Sackler School of Medicine, Sagol School of Neurosciences Tel Aviv University and was licensed from Ramot, the Business Engagement Center at Tel Aviv University. [Read more…]
Exosome Market Poised for Expansion?
The market for stem cell exosomes is a fast-growth, high potential market. Currently in its early-stages, the market is readily posed for expansion. With a limited number of market competitors and few products in clinical-stage trials, the market is ripe for disruption by new competitors and new technologies. [Read more…]
Exosome Start-up ExoCoBio Inc. raises $26.7M in Series B Funding
-
ExoCoBio is the 4th largest funded exosome startup in the world
-
ExoCoBio is using the funding to advance its exosome pharmaceutical R&D and cosmeceutical business
SEOUL, South Korea, Sept. 12, 2018 — ExoCoBio Inc. announced that it recently raised about $27 million in its series B funding. Top tier Korean investors participated in this round, including Seven Tree Equity Partners, CSQUARED Global Asset Management, TS Investment Partners, K2 Investment, Intervest, KDB Capital, Atinum Investment, GU Equity Partners, QUANTUM Ventures Korea, Platinum technology Investment.
[Read more…]
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 27
- Next Page »